Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

by NASDAQ Market News September 28, 2021

NASDAQ Market News
Click here to email author

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

Neovasc REDUCER-I Study Published in EuroIntervention Journal

Ads